USFDAJun 4, 2026, 07:36 AM
Abeona Therapeutics holds constructive Pre-IND meeting for ABO-701
AI Summary
Abeona Therapeutics Inc. held a constructive Pre-Investigational New Drug (Pre-IND) meeting with the U.S. Food and Drug Administration (FDA) on June 3, 2026. The discussion focused on ABO-701, a recently licensed engineered T-cell therapy targeting Prostate-Specific Membrane Antigen to treat prostate cancer. The company maintains its target of submitting an IND application for ABO-701 in 2027, aligning with its previously announced timeline, though it acknowledges the FDA may request further studies or data.
Key Highlights
- Abeona Therapeutics participated in a Pre-IND meeting with the FDA on June 3, 2026.
- The meeting concerned ABO-701, a novel engineered T-cell therapy for prostate cancer.
- The company believes the meeting was constructive.
- Abeona continues to target an IND application submission for ABO-701 in 2027.
- This timeline is consistent with previously stated plans.
- FDA may require additional studies or data before accepting the IND submission.
Price Impact
More from ABEO